JonesResearch downgraded Mural Oncology (MURA) to Hold from Buy without a price target after the company’s interim survival analysis failed to show any improvement in survival with treatment over control arm in platinum resistant ovarian cancer. Mural will not progress trial to final analysis and will cease development of nemvaleukin for platinum resistant ovarian cancer, the analyst tells investors in a research note. Jones now awaits “the stock to settle down following today’s news.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MURA:
- Mural Oncology downgraded to Outperform from Strong Buy at Raymond James
- Raymond James downgrades Mural Oncology after ovarian cancer failure
- Mural Oncology downgraded to Equal Weight from Overweight at Morgan Stanley
- Promising Developments in Mural Oncology Plc’s ARTISTRY-7 Trial Boost Buy Rating
- Promising Outlook for Mural Oncology: Buy Rating Driven by Nemvaleukin’s Potential and Strategic Trials